【摘要】 目的　评价异长春花碱加异环磷酰胺加顺铂(NIP)联合方案作为第一线化疗对晚期非小细胞肺癌病人的疗效及毒副作用。方法　化疗方案包括异长春花碱 2 5mg/ m2 2 0 min静脉输注第 1d和第 8d,异环磷酰胺 1.2 g/ m23 h静脉输注第 1～ 3 d,美司纳 40 0 mg～ 80 0 m g于 0、4、8h静脉推注第 1～ 3 d,顺铂 2 5 m g/ m2 2 h静脉输注第 1～ 3 d。每 3周重复疗程。结果　共 5 4例病人进入本项研究。 5 1例可评价疗效 ,5 4例可评价毒性反应。总缓解率为 5 3 % ,3例(6 % )完全缓解 ,2 4例 (4 7% )部分缓解。 16例 (31% )肿瘤稳定 ,8例 (16 % )肿瘤发展。中位缓解期 7个月 ,全组中位生存期 10个月。本化疗方案的剂量限制毒性为骨髓抑制 ,其中72 %的病人发生 3～ 4度中性粒细胞下降。结论　 NIP是治疗晚期非小细胞肺癌有效的联合化疗方案 ,毒性反应能够耐受 ,值得进一步研究更多还原

【Abstract】 Objective To evaluate the efficacy and toxicity of combination of navelbine, inosfamide and cisplatin (NIP) as first line chemotherapy in patients with advanced non small cell lung cancer (NSCLS).Methods The chemotherapy regimen consisted of navelbine 25 mg/m 2 by 20 minutes intravenous iv infusion on days 1 and 8, ifosfamide 1 2 g/m 2 by 3 hours iv infusion on days 1～3, mesna 400 mg～800 mg by iv bolus at hours 0, 4 and 8 on days 1～3 and cisplatine 25 mg/m 2 by 2 hours iv infusion on days 1～3. Courses were repeated every 3 weeks. Results Fifty four patients entered the study. Fifty one patients were evaluable for response and 54 were assessable for toxicity. The over all response rate was 53 % with 3 (6 %) CR and 24 (47 %) PR. The disease was stable in 16 patients (31 %) and was progressive in 8 patients (16 %). The median duration of response was 7 months and the median over all survival time was 10 months. The dose limiting toxicity ssociated with this regimen was myelo suppression with grade 3～4 neutrocytopenia in 72 % of patients. Conclusion The NIP combination chemotherapy is an active regimen for advanced NSCLC with tolerable toxicity and deserves further evaluation.更多还原